Interleukin-33 as a Potential Therapeutic Target in Gastric Cancer Patients: Current Insights

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Larsen KM, Minaya MK, Vaish V, Peña MMO. The role of IL-33/ST2 pathway in tumorigenesis. Int J Mol Sci. 2018;19(9):2676. doi:10.3390/ijms19092676
   PubMed Web of Science ®Google Scholar
• Afferni C, Buccione C, Andreone S, et al. The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity. Front Immunol. 2018;9:2601. doi:10.3389/fimmu.2018.02601
   PubMed Web of Science ®Google Scholar
• Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16(11):676–689. doi:10.1038/nri.2016.95
   PubMed Web of Science ®Google Scholar
• Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci. 2011;56(12):3596–3601. doi:10.1007/s10620-011-1760-5
   PubMed Web of Science ®Google Scholar
• Huang N, Cui X, Li W, Zhang C, Liu L, Li J. IL-33/ST2 promotes the malignant progression of gastric cancer via the MAPK pathway. Mol Med Rep. 2021;23(5):361. doi:10.3892/mmr.2021.12000
   PubMed Web of Science ®Google Scholar
• Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85(11):1457–1459. PMID: 9823902. doi:10.1046/j.1365-2168.1998.00940.x
   PubMed Web of Science ®Google Scholar
• Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49. doi:10.1111/apm.1965.64.1.31
   PubMedGoogle Scholar
• Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–v49. doi:10.1093/annonc/mdw350
   PubMedGoogle Scholar
• Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3(3):251–261. PMID: 22943016; PMCID: PMC3418539. doi:10.3978/j.issn.2078-6891.2012.021
   PubMedGoogle Scholar
• Berlth F, Bollschweiler E, Drebber U, Hoelscher AH, Moenig S. Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. World J Gastroenterol. 2014;20(19):5679. doi:10.3748/wjg.v20.i19.5679
   PubMed Web of Science ®Google Scholar
• Limburg P, Qiao Y-L, Mark SD, et al. Helicobacter pylori seropositivity and subsite-specific gastric cancer risks in Linxian, China. J Natl Cancer Inst. 2001;93:226–233. doi:10.1093/jnci/93.3.226
   PubMedGoogle Scholar
• Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136(2):487–490. doi:10.1002/ijc.28999
   PubMed Web of Science ®Google Scholar
• Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst. 2006;98:1445–1452. doi:10.1093/jnci/djj393
   PubMed Web of Science ®Google Scholar
• Koshiol J, Wei WQ, Kreimer AR, et al. The gastric cardia is not a target for human papillomavirus-induced carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2010;19(4):1137–1139. doi:10.1158/1055-9965.EPI-10-0089
   PubMed Web of Science ®Google Scholar
• de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–615. doi:10.1016/S1470-2045(12)70137-7
   PubMed Web of Science ®Google Scholar
• Coburn N, Cosby R, Klein L, et al. Staging and surgical approaches in gastric cancer: a systematic review. Cancer Treat Rev. 2018;63:104–115. doi:10.1016/j.ctrv.2017.12.006
   PubMed Web of Science ®Google Scholar
• Allen CJ, Pointer DT, Blumenthaler AN, et al. Chemotherapy versus chemotherapy plus chemoradiation as neoadjuvant therapy for resectable gastric adenocarcinoma: a multi-institutional analysis. Ann Surg. 2021;274:544–548. doi:10.1097/SLA.0000000000005007
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric cancer, version 2. 2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:167–192.
   PubMed Web of Science ®Google Scholar
• In H, Solsky I, Palis B, et al. Validation of the 8th edition of the AJCC TNM staging system for gastric cancer using the national cancer database. Ann Surg Oncol. 2017;24:3683–3691. doi:10.1245/s10434-017-6078-x
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Sanchez-Vega F, Jonsson P, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer genomic biomarkers in esophagogastric adenocarcinoma. Cancer Discov. 2018;8:49–58. doi:10.1158/2159-8290.CD-17-0787
   PubMed Web of Science ®Google Scholar
• Zhang S-X, Liu W, Ai B, et al. Current advances and outlook in gastric cancer chemoresistance: a review. Recent Pat Anticancer Drug Discov. 2022;17:26–41. doi:10.2174/1574892816666210929165729
   PubMed Web of Science ®Google Scholar
• Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumor Biol. 2017;39(7):1010428317714626. doi:10.1177/1010428317714626
   Google Scholar
• Chang AY, Foo KF, Koo W, et al. Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer. BMJ Open Gastroenterol. 2016;3:e000095. doi:10.1136/bmjgast-2016-000095
   PubMedGoogle Scholar
• Yoshikawa T, Rino Y, Yukawa N, Oshima T, Tsuburaya A, Masuda M. Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surg Today. 2014;44:11–21. doi:10.1007/s00595-013-0529-1
   PubMed Web of Science ®Google Scholar
• Lei ZN, Teng QX, Tian Q, et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther. 2022;7(1):358. doi:10.1038/s41392-022-01190-w
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–490. doi:10.1016/j.immuni.2005.09.015
   PubMed Web of Science ®Google Scholar
• Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007;104(1):282–287. doi:10.1073/pnas.0606854104
   PubMed Web of Science ®Google Scholar
• Zhao W, Hu Z. The enigmatic processing and secretion of interleukin-33. Cell Mol Immunol. 2010;7(4):260–262. doi:10.1038/cmi.2010.3
   PubMed Web of Science ®Google Scholar
• Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA. 2009;106(22):9021–9026. doi:10.1073/pnas.0812690106
   PubMed Web of Science ®Google Scholar
• Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014;31:31–37. doi:10.1016/j.coi.2014.09.004
   PubMed Web of Science ®Google Scholar
• Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989;258(2):301–304. doi:10.1016/0014-5793(89)81679-5
   PubMed Web of Science ®Google Scholar
• Tominaga S, Yokota T, Yanagisawa K, Tsukamoto T, Takagi T, Tetsuka T. Nucleotide sequence of a complementary DNA for human ST2. Biochim Biophys Acta. 1992;1171(2):215–218. doi:10.1016/0167-4781(92)90125-j
   PubMedGoogle Scholar
• Yanagisawa K, Takagi T, Tsukamoto T, Tetsuka T, Tominaga S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 1993;318(1):83–87. doi:10.1016/0014-5793(93)81333-u
   PubMed Web of Science ®Google Scholar
• Hardman C, Ogg G. Interleukin-33, friend and foe in type-2 immune responses. Curr Opin Immunol. 2016;42:16–24. doi:10.1016/j.coi.2016.05.004
   PubMed Web of Science ®Google Scholar
• Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 1994;13(5):1176–1188. doi:10.1002/j.1460-2075.1994.tb06367.x
   PubMed Web of Science ®Google Scholar
• Tominaga S, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Komatsu N. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun. 1999;264(1):14–18. doi:10.1006/bbrc.1999.1469
   PubMed Web of Science ®Google Scholar
• Tago K, Noda T, Hayakawa M, et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun. 2001;285(5):1377–1383. doi:10.1006/bbrc.2001.5306
   PubMed Web of Science ®Google Scholar
• Iwahana H, Hayakawa M, Kuroiwa K, et al. Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV. Biochim Biophys Acta. 2004;1681(1):1–14. doi:10.1016/j.bbaexp.2004.08.013
   PubMedGoogle Scholar
• Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy. 2002;32(10):1520–1526. doi:10.1046/j.1365-2745.2002.01494.x
   PubMed Web of Science ®Google Scholar
• Millar NL, O’Donnell C, McInnes IB, Brint E. Wounds that heal and wounds that don’t - the role of the IL-33/ST2 pathway in tissue repair and tumorigenesis. Semin Cell Dev Biol. 2017;61:41–50. doi:10.1016/j.semcdb.2016.08.007
   PubMed Web of Science ®Google Scholar
• Funakoshi-Tago M, Tago K, Hayakawa M, et al. TRAF6 is a critical signal transducer in IL-3 signalling pathway. Cell Signal. 2008;20(9):1679–1686. doi:10.1016/j.cellsig.2008.05.013
   PubMed Web of Science ®Google Scholar
• Milovanovic M, Volarevic V, Radosavljevic G, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res. 2012;52(1–2):89–99. doi:10.1007/s12026-012-8283-9
   PubMed Web of Science ®Google Scholar
• O’Donnell C, Mahmoud A, Keane J, et al. An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. Br J Cancer. 2016;114(1):37–43. doi:10.1038/bjc.2015.433
   PubMed Web of Science ®Google Scholar
• Akimoto M, Takenaga K. Role of the IL-33/ST2L axis in colorectal cancer progression. Cell Immunol. 2019;343:103740. doi:10.1016/j.cellimm.2017.12.014
   PubMed Web of Science ®Google Scholar
• Lu B, Yang M, Wang Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med. 2016;94(5):535–543. doi:10.1007/s00109-016-1397-0
   PubMed Web of Science ®Google Scholar
• Jovanovic I, Radosavljevic G, Mitrovic M, et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol. 2011;41(7):1902–1912. doi:10.1002/eji.201141417
   PubMed Web of Science ®Google Scholar
• Jovanovic IP, Pejnovic NN, Radosavljevic GD, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer. 2014;134(7):1669–1682. doi:10.1002/ijc.28481
   PubMed Web of Science ®Google Scholar
• Xiao P, Wan X, Cui B, et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology. 2015;5(1):e1063772. doi:10.1080/2162402X.2015.1063772
   PubMed Web of Science ®Google Scholar
• Blatner NR, Bonertz A, Beckhove P, et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci USA. 2010;107(14):6430–6435. doi:10.1073/pnas.0913683107
   PubMed Web of Science ®Google Scholar
• Kim JY, Lim SC, Kim G, Yun HJ, Ahn SG, Choi HS. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene. 2015;34(38):4928–4938. doi:10.1038/onc.2014.418
   PubMed Web of Science ®Google Scholar
• Hu H, Sun J, Wang C, et al. IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties. Biochem Biophys Res Commun. 2017;485(3):643–650. doi:10.1016/j.bbrc.2017.02.080
   PubMed Web of Science ®Google Scholar
• He Z, Chen L, Souto FO, et al. Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc Min/+ mice. Sci Rep. 2017;7(1):5520. doi:10.1038/s41598-017-05716-z
   PubMed Web of Science ®Google Scholar
• Akimoto M, Maruyama R, Takamaru H, Ochiya T, Takenaga K. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment. Nat Commun. 2016;7:13589. doi:10.1038/ncomms13589
   PubMed Web of Science ®Google Scholar
• Fang M, Li Y, Huang K, et al. IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment. Cancer Res. 2017;77(10):2735–2745. doi:10.1158/0008-5472.CAN-16-1602
   PubMed Web of Science ®Google Scholar
• Maywald RL, Doerner SK, Pastorelli L, et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci USA. 2015;112(19):E2487–E2496. doi:10.1073/pnas.1422445112
   PubMed Web of Science ®Google Scholar
• Mertz KD, Mager LF, Wasmer MH, et al. The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology. 2015;5(1):e1062966. doi:10.1080/2162402X.2015.1062966
   PubMed Web of Science ®Google Scholar
• Zhang Y, Davis C, Shah S, et al. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol Carcinog. 2017;56(1):272–287. doi:10.1002/mc.22491
   PubMed Web of Science ®Google Scholar
• Liu X, Zhu L, Lu X, et al. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun. 2014;453(3):486–492. doi:10.1016/j.bbrc.2014.09.106
   PubMed Web of Science ®Google Scholar
• Wang K, Shan S, Yang Z, et al. IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model. Oncotarget. 2017;8(40):68571–68582. doi:10.18632/oncotarget.19786
   PubMedGoogle Scholar
• Akimoto M, Hayashi JI, Nakae S, Saito H, Takenaga K. Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. Cell Death Dis. 2016;7(1):e2057. doi:10.1038/cddis.2015.418
   PubMedGoogle Scholar
• Yang Z, Gao X, Wang J, Xu L, Zheng Y, Xu Y. Interleukin-33 enhanced the migration and invasiveness of human lung cancer cells. Onco Targets Ther. 2018;11:843–849. doi:10.2147/OTT.S155905
   PubMed Web of Science ®Google Scholar
• Wang C, Chen Z, Bu X, et al. IL-33 signalling fuels outgrowth and metastasis of human lung cancer. Biochem Biophys Res Commun. 2016;479(3):461–468. doi:10.1016/j.bbrc.2016.09.081
   PubMed Web of Science ®Google Scholar
• Chen SF, Nieh S, Jao SW, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol. 2013;231(2):180–189. doi:10.1002/path.4226
   PubMed Web of Science ®Google Scholar
• Yamada D, Rizvi S, Razumilava N, et al. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology. 2015;61(5):1627–1642. doi:10.1002/hep.27687
   PubMed Web of Science ®Google Scholar
• Li J, Razumilava N, Gores GJ, et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest. 2014;124(7):3241–3251. doi:10.1172/JCI73742
   PubMed Web of Science ®Google Scholar
• Gao K, Li X, Zhang L, et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett. 2013;335(2):463–471. doi:10.1016/j.canlet.2013.03.002
   PubMed Web of Science ®Google Scholar
• Gao X, Wang X, Yang Q, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol. 2015;194(1):438–445. doi:10.4049/jimmunol.1401344
   PubMed Web of Science ®Google Scholar
• Dominguez D, Ye C, Geng Z, et al. Exogenous IL-33 restores dendritic cell activation and maturation in established cancer. J Immunol. 2017;198(3):1365–1375. doi:10.4049/jimmunol.1501399
   PubMed Web of Science ®Google Scholar
• Kim J, Kim W, Moon UJ, et al. Intratumorally establishing type 2 innate lymphoid cells blocks tumor growth. J Immunol. 2016;196(5):2410–2423. doi:10.4049/jimmunol.1501730
   PubMed Web of Science ®Google Scholar
• Lucarini V, Ziccheddu G, Macchia I, et al. IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology. 2017;6(6):e1317420. doi:10.1080/2162402X.2017.1317420
   PubMed Web of Science ®Google Scholar
• Saranchova I, Han J, Huang H, et al. Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker interleukin-33. Sci Rep. 2016;6(1):30555. doi:10.1038/srep30555
   PubMedGoogle Scholar
• Eissmann MF, Dijkstra C, Wouters MA, et al. Interleukin 33 signaling restrains sporadic colon cancer in an interferon-γ-dependent manner. Cancer Immunol Res. 2018;6(4):409–421. doi:10.1158/2326-6066.CIR-17-0218
   PubMed Web of Science ®Google Scholar
• Malik A, Sharma D, Zhu Q, et al. IL-33 regulates the IgA-microbiota axis to restrain IL-1α-dependent colitis and tumorigenesis. J Clin Invest. 2016;126(12):4469–4481. doi:10.1172/JCI88625
   PubMed Web of Science ®Google Scholar
• Qin L, Dominguez D, Chen S, et al. Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. Oncotarget. 2016;7(38):61069–61080. doi:10.18632/oncotarget.11179
   PubMedGoogle Scholar
• Duault C, Betous D, Bezombes C, et al. IL-33-expanded human Vγ9Vδ2 T cells have anti-lymphoma effect in a mouse tumor model. Eur J Immunol. 2017;47(12):2137–2141. doi:10.1002/eji.201747093
   PubMed Web of Science ®Google Scholar
• Bergis D, Kassis V, Radeke HH. High plasma sST2 levels in gastric cancer and their association with metastatic disease. Cancer Biomark. 2016;16(1):117–125. doi:10.3233/CBM-150547
   PubMed Web of Science ®Google Scholar
• Chang CP, Hu MH, Hsiao YP, Wang YC. ST2 signaling in the tumor microenvironment. Adv Exp Med Biol. 2020;1240:83–93. doi:10.1007/978-3-030-38315-2_7
   PubMed Web of Science ®Google Scholar
• Kuo CJ, Chen CY, Lo HR, et al. Helicobacter pylori induces IL-33 production and recruits ST-2 to lipid rafts to exacerbate inflammation. Cells. 2019;8(10):1290. doi:10.3390/cells8101290
   PubMed Web of Science ®Google Scholar
• Lv Q, Xia Q, Li A, Wang Z. The potential role of IL1RAP on tumor microenvironment-related inflammatory factors in stomach adenocarcinoma. Technol Cancer Res Treat. 2021;20:1533033821995282. doi:10.1177/1533033821995282
   Web of Science ®Google Scholar
• Buzzelli JN, Chalinor HV, Pavlic DI, et al. IL33 is a stomach alarmin that initiates a skewed Th2 response to injury and infection. Cell Mol Gastroenterol Hepatol. 2015;1(2):203–221.e3. doi:10.1016/j.jcmgh.2014.12.003
   PubMedGoogle Scholar
• Meyer AR, Goldenring JR. Injury, repair, inflammation and metaplasia in the stomach. J Physiol. 2018;596(17):3861–3867. doi:10.1113/JP275512
   PubMed Web of Science ®Google Scholar
• Bie Q, Zhang P, Su Z, et al. Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer. J Immunol Res. 2014;2014:923135. doi:10.1155/2014/923135
   PubMed Web of Science ®Google Scholar
• Petersen CP, Meyer AR, De Salvo C, et al. A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut. 2018;67(5):805–817. doi:10.1136/gutjnl-2016-312779
   PubMed Web of Science ®Google Scholar
• De Salvo C, Pastorelli L, Petersen CP, et al. Interleukin 33 triggers early eosinophil-dependent events leading to metaplasia in a chronic model of gastritis-prone mice. Gastroenterology. 2021;160(1):302–316.e7. doi:10.1053/j.gastro.2020.09.040
   PubMed Web of Science ®Google Scholar
• Eissmann MF, Dijkstra C, Jarnicki A, et al. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization. Nat Commun. 2019;10(1):2735. doi:10.1038/s41467-019-10676-1
   PubMedGoogle Scholar
• Tran CP, Scurr M, O’Connor L, et al. IL-33 promotes gastric tumour growth in concert with activation and recruitment of inflammatory myeloid cells. Oncotarget. 2022;13:785–799. doi:10.18632/oncotarget.28238
   PubMedGoogle Scholar
• Lv Y, Tian W, Teng Y, et al. Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression. J Adv Res. 2023. PMID: 37086778. doi:10.1016/j.jare.2023.04.013
   Google Scholar
• Zhou Q, Wu X, Wang X, et al. The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-α/IL-33/ST2L signaling promotes gastric cancer metastasis. Oncogene. 2020;39(7):1414–1428. doi:10.1038/s41388-019-1078-x
   PubMed Web of Science ®Google Scholar
• Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ, Hu WH. IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Dig Dis Sci. 2015;60(5):1265–1272. doi:10.1007/s10620-014-3463-1
   PubMed Web of Science ®Google Scholar
• Kwon JW, Seok SH, Kim S, et al. A synergistic partnership between IL-33/ST2 and Wnt pathway through Bcl-xL drives gastric cancer stemness and metastasis. Oncogene. 2023;42(7):501–515. doi:10.1038/s41388-022-02575-5
   PubMed Web of Science ®Google Scholar
• Ye XL, Zhao YR, Weng GB, et al. IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance. Oncol Rep. 2015;33(6):2746–2752. doi:10.3892/or.2015.3898
   PubMed Web of Science ®Google Scholar
• Hu W, Wu C, Li X, et al. Serum IL-33 level is a predictor of progression-free survival after chemotherapy. Oncotarget. 2017;8(21):35116–35123. doi:10.18632/oncotarget.16627
   PubMedGoogle Scholar
• Huang C, Liu J, He L, et al. The long noncoding RNA noncoding RNA activated by DNA damage (NORAD)-microRNA-496-Interleukin-33 axis affects carcinoma-associated fibroblasts-mediated gastric cancer development. Bioengineered. 2021;12(2):11738–11755. doi:10.1080/21655979.2021.2009412
   PubMed Web of Science ®Google Scholar
• Jeong H, Lee B, Kim KH, et al. WFDC2 promotes spasmolytic polypeptide-expressing metaplasia through the up-regulation of IL33 in response to injury. Gastroenterology. 2021;161(3):953–967.e15. doi:10.1053/j.gastro.2021.05.058
   PubMed Web of Science ®Google Scholar
• Deng K, Wang H, Shan T, et al. Tristetraprolin inhibits gastric cancer progression through suppression of IL-33. Sci Rep. 2016;6:24505. doi:10.1038/srep24505
   PubMed Web of Science ®Google Scholar
• Zeng X, Yang M, Ye T, et al. Mitochondrial GRIM-19 loss in parietal cells promotes spasmolytic polypeptide-expressing metaplasia through NLR family pyrin domain-containing 3 (NLRP3)-mediated IL-33 activation via a reactive oxygen species (ROS) -NRF2- Heme oxygenase-1(HO-1)-NF-кB axis. Free Radic Biol Med. 2023;202:46–61. PMID: 36990300. doi:10.1016/j.freeradbiomed.2023.03.024
   PubMed Web of Science ®Google Scholar
• Pisani LF, Tontini GE, Gentile C, et al. Proinflammatory interleukin-33 induces dichotomic effects on cell proliferation in normal gastric epithelium and gastric cancer. Int J Mol Sci. 2021;22(11):5792. doi:10.3390/ijms22115792
   PubMed Web of Science ®Google Scholar
• Hu W, Li X, Li Q, et al. Interleukin-33 expression does not correlate with survival of gastric cancer patients. Pathol Oncol Res. 2017;23(3):615–619. doi:10.1007/s12253-016-0167-1
   PubMed Web of Science ®Google Scholar
• Liu QH, Zhang JW, Xia L, et al. Clinical implications of interleukins-31, 32, and 33 in gastric cancer. World J Gastrointest Oncol. 2022;14(9):1808–1822. doi:10.4251/wjgo.v14.i9.1808
   PubMed Web of Science ®Google Scholar
• Patel TH, Cecchini M. Targeted therapies in advanced gastric cancer. Curr Treat Options Oncol. 2020;21(9):70. doi:10.1007/s11864-020-00774-4
   PubMed Web of Science ®Google Scholar